MaRfaNomicA: Transcriptomic Study of Adult Population With Marfan Syndrome
Study Details
Study Description
Brief Summary
This project is designed to discover circulating biomarkers for aortic aneurysms in adults affected by Marfan Syndrome (MFS). The first aim is to identify circulating transcripts, protein-coding (mRNA) and not (ncRNAs), which show differential expression between three groups of adult patients affected by MFS, based on: presence or absence of thoracic aortic aneurysms (TAA) and indication of TAA-surgery. This obtained TAA_MFS_signature will then be correlated to fundamental biological parameters, like cytokines and chemokines relevant during inflammation and transcriptomic as well as epigenetics changes in aortic aneurysm tissue. Furthermore, the association of TAA_MFS_signature to genetic, clinical and instrumental parameters at present used for diagnosis and treatment, will be evaluated.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
The investigators will collect peripheral blood and aortic aneurysm tissues specimens from consenting subjects. For all three groups of MFS patients, total RNA will be isolated from peripheral whole blood, plasma and peripheral blood mononuclear cell (PBMC) and processed for transcriptomic analyses by RNAseq. Plasma will be used to determine cytokine and chemokine levels, using a luminex panel designed for inflammation biomarkers (serum proteomics). For all patients undergoing surgery, tissue specimens will be used for transcriptomic and epigenetic analysis, histological sections and serum proteomics.
Study Design
Outcome Measures
Primary Outcome Measures
- Transcriptomic Signature in adult patients suffering of affected by Marfan syndrome [year 1-5]
Identification of differences in transcript-expression between Marfan patients with or without thoracic aortic aneurysms (TAA) and with indication of TAA-surgery.
Eligibility Criteria
Criteria
Inclusion Criteria:
General criteria:
-
Clinically and genetically determined Marfan syndrome (according to the revised Ghent-criteria 2010)
-
Signed informed consent
-
Patient receiving regular pharmacological prophylaxis or newly diagnosed patients
Population without thoracic aortic aneurysms (TAA) Patients with clinically and genetically determined Marfan syndrome, presenting thoracic aortic diameters within established normal limits (mm and base Z-score).
Population with TAA "stable dimensions" Patients with clinically and genetically determined Marfan syndrome, presenting stable values for dimension / Z-score of the aortic root during the 12 months preceding the enrolment.
Population with TAA with surgery indication:
-
Patients with clinically and genetically determined Marfan syndrome, presenting indication for surgical correctional according to the relevant International guidelines
-
Trend of uncontrolled increase of aortic diameter compared to previous measurements
-
Aortic ectasia associated to a clinically significant valve dysfunction
-
Evaluation of cut-off for surgical intervention dependant also on familial dissection
Exclusion Criteria:
-
Patients with chronic or acute inflammation states, like: chronic liver disease, chronic renal insufficiency (creatinine > 1.5 mg/dl) and diseases affecting the thyroid apparatus.
-
Pregnancy
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Irccs Policlinico San Donato | San Donato Milanese | Milan | Italy | 20097 |
Sponsors and Collaborators
- IRCCS Policlinico S. Donato
Investigators
- Principal Investigator: Fabio Martelli, Dr, IRCCS Policlinico S. Donato
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- MaRfaNomicA